Joel Gelfand of the Perelman School of Medicine comments on a study that suggests exercise is connected to a lower risk of psoriasis.
Perelman School of Medicine
Philip Gehrman of the Perelman School of Medicine shares his thoughts on a new study about sleepwalking.
Ben Voight of the Perelman School of Medicine is mentioned as co-author of a study about HDL levels.
A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab. This proof-of-concept study is published this week in Science Translational Medicine.
Arthur Caplan of the Perelman School of Medicine comments on ethical concerns associated with at-home HIV testing kits.
A new study published by researchers at the Perelman School of Medicine at the University of Pennsylvania, the Broad Institute, and Massachusetts General Hospital, challenges the conventional concept that raising a person's HDL levels (good cholesterol) will always help lower their risk of a heart attack.
Media Contact:Jessica Mikulski | Jessica.firstname.lastname@example.org | 215-349-8360May 9, 2012
The American Heart Association (AHA) announced today that they have made their first investment through the Science & Technology Accelerator Program into CytoVas, LLC. The company was founded by Jonni S.
PHILADELPHIA — Targeted drug delivery is one of the more enticing applications of nanotechnology; by designing pharmaceuticals on an atomic scale, engineers hope to get them attacking diseases with newfound precision and efficiency.
A team of University of Pennsylvania researchers has recently been recognized by the National Science Foundation for the development of computer models that will be instrumental in improving these designs.